ABC | Volume 111, Nº1, Julho 2018

Ponto de Vista Behr et al PCSK9 em pacientes com risco cardiovascular Arq Bras Cardiol. 2018; 111(1):104-108 13. Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune Neto A et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq Bras Cardiol 2017; 109(2Supl.1):1-76. 14. Lloyd-DM,Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus. J Am Coll Cardiol. 2016;68(1):92–125. 15. Cook RJ, SackettDL.The number needed to treat: a clinically useful measure of treatment effect. BMJ.1995;310(6977):452-4. 16. Robinson JG, Huijgen R, Ray K, Persons J, Kastelein JJ, Pencina MJ. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol.2016;68(22):2412-21. Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 17. LaufsU,DescampsOS,CatapanoAL,PackardCJ.Understanding IMPROVE- IT and the cardinal role of LDL-C lowering in CVD prevention. Eur Heart J. 2014;35:1996-2000. 18. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta- analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376(9753):1670-81. 19. Van der Leeuw J, Oemrawsingh RM, van der Graaf Y, BrugtsJJ, Deckers JW, et al. Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease — Results from EUROPA. Int J Cardiol. 2015;182:194-9. 20. Steel N.Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. BMJ. 2000;320(7247):1446–7. 108